Please assess the completion status of the following clinical trial:

Trial Title: Can we Use Intravenous Injection of Tranexamic Acid in Routine Practice With Active Management of the Third Stage of Labor?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* gestational age between 37 and 42 weeks,~* live fetus,~* cephalic presentation,~* vaginal birth.~* Patients who had a risk factors for PPH, such as multiple gestation, polyhydramnios, fetal macrosomia, antepartum hemorrhage, anemia (haemoglobin concentration \< 8 g/dL), severe pre-eclampsia, or coagulopathy~Exclusion Criteria:~* placenta previa,~* placental abruption,~* cesarean section or any uterine scar, abnormal placentation (accreta, increta, or percreta),~* a current or previous history of significant disease, including heart disease, liver, renal disorders.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- tranexamic acid (Type: ACTIVE_COMPARATOR): TA administered intravenously over a 5 min period at delivery of the anterior shoulder
- saline (Type: NO_INTERVENTION): 10 mL of saline was administered intravenously over a 5 min period at delivery of the anterior shoulder

Based on this trial design, predict the completion outcome and termination type (if applicable).